Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

Clinical and molecular insights into BCG immunotherapy for melanoma

(2020) M. Kremenovic et al.   JOURNAL OF INTERNAL MEDICINE

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

(2020) Shumei Kato et al.   OncoImmunology

Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations

(2020) Elisa Gremese et al.   CLINICAL IMMUNOLOGY

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy

(2020) Afsheen Raza et al.   Journal of Translational Medicine

LAG3(LAG-3,CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma

(2020) Niklas Klümper et al.   Journal for ImmunoTherapy of Cancer

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis

(2020) Robin Park et al.   Frontiers in Oncology

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features

(2019) Michele Porcu et al.   Cancers

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

(2019) Prabhakaran Kumar et al.   SEMINARS IN CANCER BIOLOGY

Immunotherapy and targeted therapy combinations in metastatic breast cancer

(2019) Francisco J Esteva et al.   LANCET ONCOLOGY

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

(2019) Deborah B Doroshow et al.   CLINICAL CANCER RESEARCH

T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma

(2019) Fabienne Lucas et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer

(2019) Takeo Shibata et al.   CANCER TREATMENT REVIEWS

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

(2019) Joseph L. Benci et al.   CELL

LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer

(2019) Cinzia Solinas et al.   Cancers

The microenvironment in myeloma

(2019) Oliver C. Lomas et al.   CURRENT OPINION IN ONCOLOGY

The CC′ loop of IgV domains of the immune checkpoint receptors, plays a key role in receptor:ligand affinity modulation

(2019) Shankar V. Kundapura et al.   Scientific Reports

CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions

(2018) Masao Hashimoto et al.   Annual Review of Medicine

T Cell Dysfunction in Cancer

(2018) Daniela S. Thommen et al.   CANCER CELL

In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro

(2018) Ngoc Pham Minh et al.   INTERNATIONAL JOURNAL OF CANCER

A Believer’s Overview of Cancer Immunosurveillance and Immunotherapy

(2018) Olivera J. Finn   JOURNAL OF IMMUNOLOGY

Vaccination-induced skin-resident memory CD8+ T cells mediate strong protection against cutaneous melanoma

(2018) Felipe Gálvez-Cancino et al.   OncoImmunology

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma

(2018) Ajay K. Nooka et al.   JAMA Oncology

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma

(2017) J Bae et al.   LEUKEMIA

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

(2017) C S Chim et al.   LEUKEMIA

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

(2017) Sathana Dushyanthen et al.   Nature Communications

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

(2017) Jie Bai et al.   Oncotarget

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities

(2017) Ricardo Costa et al.   Oncotarget

Trial watch: Immune checkpoint blockers for cancer therapy

(2017) Claire Vanpouille-Box et al.   OncoImmunology

Galectin 3 as a guardian of the tumor microenvironment

(2016) Peter P. Ruvolo   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

(2015) T. Kouo et al.   Cancer Immunology Research

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody

(2014) L. Karyampudi et al.   CANCER RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

(2013) Dung T. Le et al.   JOURNAL OF IMMUNOTHERAPY

A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma

(2012) Jooeun Bae et al.   BRITISH JOURNAL OF HAEMATOLOGY

Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

(2012) J. Bae et al.   CLINICAL CANCER RESEARCH

Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders

(2011) Jooeun Bae et al.   BRITISH JOURNAL OF HAEMATOLOGY

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma

(2011) J Bae et al.   LEUKEMIA

Galectin-3C Inhibits Tumor Growth and Increases the Anticancer Activity of Bortezomib in a Murine Model of Human Multiple Myeloma

(2011) Leonardo Mirandola et al.   PLoS One

A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice

(2010) N. Demotte et al.   CANCER RESEARCH

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse

(2009) H.-Y. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA